Peptide nanomaterials as targeted therapies for glioblastoma

Diana Leite Moreira, Katerina Lalatsa

Research output: Contribution to conferenceAbstractpeer-review

146 Downloads (Pure)


Brain diseases are responsible for 12% of global deaths and their treatment could benefit from the use of highly potent and specific pharmaceuticals with low inherent toxicity and immunogenicity such as neuropeptides 1. However, for neuropeptide therapies to be realised, peptides need to be able to cross the blood-brain barrier (BBB) and possess enhanced enzymatic stability to ensure adequate brain bioavailability. Lipidisation of peptides has been proven to be a useful strategy to enhance enzymatic stability and BBB permeability, while increasing the amphiphilicity of neuropeptides allows their self-assembly in well-defined nanostructures 2,3. We have developed a neuropeptide amphiphile able to self-assemble and entrap brain impermeable drugs, which; possess enhanced stability to enzymatic degradation, permeates the BBB (all human in vitro BBB model) and targets receptors overexpressed in glioblastoma cells resulting in a novel targeted nanomedicine with a strong anti-proliferative and apoptotic effects in vitro. The proposed nanomedicine can be readily translated and proof of concept in an animal model is under way.

[1] Lalatsa, A., et al. Molecular Pharmaceutics 2014, 11, 1081-1093.
[2] Lalatsa, A., et al. Molecular Pharmaceutics 2012, 9, 1665-1680.
[3] Lalatsa, A., et al. Journal of Controlled Release 2015, 197, 87-96.

Published in - Journal of Interdisciplinary Medicine, Vol. 1, Issue 2.
Original languageEnglish
Number of pages1
Publication statusPublished - Jun 2016
EventBritish Society for Nanomedicine Annual Conference - Swansea University, Swansea, United Kingdom
Duration: 11 Aug 201612 Aug 2016


ConferenceBritish Society for Nanomedicine Annual Conference
Country/TerritoryUnited Kingdom


  • Peptide Amphiphiles
  • Brain Cancers
  • Targeted Delivery


Dive into the research topics of 'Peptide nanomaterials as targeted therapies for glioblastoma'. Together they form a unique fingerprint.

Cite this